Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns. Read more about Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns.
Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice. Read more about Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice.
PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study. Read more about PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study.
Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. Read more about Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.
RESIST-PC: U.S. Academic Foray into PSMA Theranostic Trials. Read more about RESIST-PC: U.S. Academic Foray into PSMA Theranostic Trials.
A Comprehensive Assessment of 68Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients. Read more about A Comprehensive Assessment of 68Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients.
Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects. Read more about Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects.
A Path to Qualification of PET/MRI Scanners for Multicenter Brain Imaging Studies: Evaluation of MRI-Based Attenuation Correction Methods Using a Patient Phantom. Read more about A Path to Qualification of PET/MRI Scanners for Multicenter Brain Imaging Studies: Evaluation of MRI-Based Attenuation Correction Methods Using a Patient Phantom.
Perspectives on Radiopharmaceutical Agents from the FDA: A Conversation between Lou Marzella, Johannes Czernin, and Thomas Hope. Read more about Perspectives on Radiopharmaceutical Agents from the FDA: A Conversation between Lou Marzella, Johannes Czernin, and Thomas Hope.
Longitudinal Imaging of T Cells and Inflammatory Demyelination in a Preclinical Model of Multiple Sclerosis Using 18F-FAraG PET and MRI. Read more about Longitudinal Imaging of T Cells and Inflammatory Demyelination in a Preclinical Model of Multiple Sclerosis Using 18F-FAraG PET and MRI.
